AnaptysBio Inc (ANAB)
20.17
-0.58
(-2.80%)
USD |
NASDAQ |
Nov 14, 16:00
20.23
+0.06
(+0.30%)
After-Hours: 20:00
AnaptysBio Research and Development Expense (Quarterly): 42.21M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 42.21M |
| June 30, 2024 | 42.00M |
| March 31, 2024 | 37.04M |
| December 31, 2023 | 33.52M |
| September 30, 2023 | 30.88M |
| June 30, 2023 | 32.92M |
| March 31, 2023 | 34.96M |
| December 31, 2022 | 23.37M |
| September 30, 2022 | 22.06M |
| June 30, 2022 | 20.84M |
| March 31, 2022 | 22.52M |
| December 31, 2021 | 26.78M |
| September 30, 2021 | 22.22M |
| June 30, 2021 | 25.31M |
| March 31, 2021 | 24.18M |
| December 31, 2020 | 21.57M |
| September 30, 2020 | 19.54M |
| June 30, 2020 | 17.95M |
| March 31, 2020 | 20.97M |
| December 31, 2019 | 21.43M |
| September 30, 2019 | 29.93M |
| Date | Value |
|---|---|
| June 30, 2019 | 27.35M |
| March 31, 2019 | 20.63M |
| December 31, 2018 | 15.92M |
| September 30, 2018 | 17.88M |
| June 30, 2018 | 10.58M |
| March 31, 2018 | 11.81M |
| December 31, 2017 | 7.606M |
| September 30, 2017 | 6.697M |
| June 30, 2017 | 7.205M |
| March 31, 2017 | 7.935M |
| December 31, 2016 | 5.016M |
| September 30, 2016 | 3.282M |
| June 30, 2016 | 2.335M |
| March 31, 2016 | 4.786M |
| December 31, 2015 | 6.572M |
| September 30, 2015 | 4.343M |
| June 30, 2015 | 3.325M |
| March 31, 2015 | 3.064M |
| December 31, 2014 | 2.605M |
| September 30, 2014 | 2.131M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
17.95M
Minimum
Jun 2020
42.21M
Maximum
Sep 2024
27.11M
Average
23.78M
Median
Research and Development Expense (Quarterly) Benchmarks
| Eli Lilly and Co | 2.734B |
| Regeneron Pharmaceuticals Inc | 1.272B |
| Ligand Pharmaceuticals Inc | 5.675M |
| Agios Pharmaceuticals Inc | 72.46M |
| ADMA Biologics Inc | 0.412M |